Novavax Global Commercial Operations and COVID-19 Vaccine Update
Ongoing clinical studies with NVX-CoV2373 and variant vaccines
Study 301
U.S. and Mexico
N = 29,945 (adults)
N = 2,247 (12- <18)
South Africa
Study 505
N = 384 (adults)
•
Study 312
Lot-to-lot
Extension
U.S.
N = 200 (adults)
·
Reactogenicity & immunology of dose 3 & dose 4 homologous boost in adults and
adolescents
Reactogenicity & immunogenicity of different 2- & 3-dose schedules in HIV+ and HIV-
Benefit of second NVX-CoV2373 boost in people who were primed with mRNA vaccine
Study 503
Pediatric
U.S., Latin America, Europe,
APAC, South Africa
N=1,200 (611)
N=~1,200 (2-5)
N=1,200 (6mo - 2)
Safety & effectiveness in pediatric populations (global licensure enabling)
Dosage level confirmation in all pediatric age groups
•
Includes crossover and 3-dose schedule
Study 311
Strain-Change
Part 2
Australia
Ongoing
N = ~750 (adults)
N=-600 (12-17)
novavax
.
Immunology of monovalent or bi-valent as a booster in adults (BA.5) and adolescents (BA.5)
© 2023 NOVAVAX. All rights reserved.
27View entire presentation